Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001919246-26-000052
Filing Date
2026-04-06
Accepted
2026-04-06 17:01:00
Documents
1
Period of Report
2026-04-02

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1775509257.html 4  
1 FORM 4 wk-form4_1775509257.xml 4 5980
  Complete submission text file 0001919246-26-000052.txt   7739
Mailing Address C/O AURINIA PHARMACEUTICALS INC. #140, 14315-118 AVENUE EDMONTON Alberta, Canada T5L 4S6
Business Address
Greenleaf Peter (Reporting) CIK: 0001363683 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41964 | Film No.: 26841986

Mailing Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703
Business Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703 919-908-2422
Pelthos Therapeutics Inc. (Issuer) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: NV | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)